Exosomes are small vesicles ranging in size from 30 nm to 100 nm that are released both constitutively and upon stimulation from a variety of cell types. They are found in a number of biological fluids and are known to carry a variety of proteins, lipids, and nucleic acid molecules. Originally thought to be little more than reservoirs for cellular debris, the roles of exosomes regulating biological processes and in diseases are increasingly appreciated.
Introduction
The HIV-1 epidemic continues to have a significant impact throughout the world. As of 2013, approximately 35 million people worldwide were living with HIV, and 2.1 million of these were newly infected individuals 1 . Prevention strategies and increased access to antiretroviral therapy have been helpful in reducing the overall acquisition of HIV. However, individual populations are still experiencing rises in the acquisition of HIV 1 . Thus, there is a need for continued efforts to address this epidemic.
One of the strongest predictors of HIV disease progression is chronic immune activation (CIA) [2] [3] [4] [5] [6] [7] [8] [9] [10] . Defined by persistently high levels of detectable cytokines and elevated expression markers on the surface of T lymphocytes, CIA has been attributed to: i) continuous dendritic cell production of Type I IFN 11 ; (ii) direct immune activation driven by HIV proteins Tat, Nef and gp120 12 ; (iii) translocation of bacterial proteins in gut associated immune cells 6 . However, the exact mechanism(s) underlying chronic, systemic immune activation in HIV infection remain to be fully elucidated.
Our research group and others have demonstrated a role of exosomes in HIV pathogenesis [15] [16] [17] [18] . Our group has determined that the Nef protein is excreted from infected cells in exosomes 15 , and exosomal Nef (exNef) is present in the plasma of HIV-infected individuals at nanogram levels 18 . We have shown that bystander CD4+ T-cells exposed to exNef resulted in activation-induced cell death dependent on the CXCR4 pathway 19, 20 . Alternatively, monocyte/macrophages were refractory to exNef-induced apoptosis, but exhibited altered cellular functions and cytokine expression. Most recently, our group has shown exosomes isolated from the plasma of HIV-infected individuals contain a variety of proinflammatory cytokines. Further, naïve peripheral blood mononuclear cells exposed to plasma-derived exosomes from HIV-infected patients induced expression of CD38 on naïve and central memory CD4+ and CD8+ T cells. This likely contributes to systemic inflammation and viral propagation via bystander cell activation 21 , and suggests that exosomes play a significant role in HIV pathogenesis.
In investigating the role of exosomes in HIV pathogenesis, one challenge is developing techniques to efficiently separate exosomes from HIV particles while maintaining the exosomal content as well as their functional immune modulatory capability. Several methods have been described . Because of their small size and low density (exosomes float at a density of 1.15 -1.19 g/ml), differential ultracentrifugation and/or ultrafiltration are the most commonly used techniques for exosome isolation 23 . However, HIV-infected cell culture supernatants and patients' plasma contain both exosomes and HIV-1 viral particles. Exosomes and HIV-1 particles are very similar in both size and density. Alternatively, taking advantage of the expression of unique exosomal markers such as CD63, CD45, and CD81, exosomes have been isolated using immunoaffinity capture methods 23 . This procedure can separate virus from exosomes. However, the drawback of this technique is the tight attachment of antibodies to the purified exosomes, which could interfere with assessment of the immunomodulatory potential of exosomes in culture.
To address these limitations, we developed a procedure for purification of exosomes from HIV particles in human plasma modified from Cantin and coworkers 22 using Iodixanol velocity gradients. Exosomes were found to segregate in the low-density/upper fractions of iodixanol gradients, whereas virus particles segregated in the high-density/lower fractions. Virus particles were identified by p24 ELISA and exosomes were identified using exosome markers AChE, CD9, CD63, and CD45. The upper low-density fractions collected contained exosomes which were negative for HIV-1 p24 contamination. The efficient purification and separation of exosomes from HIV particles in human plasma allows for accurate examination of the content of exosomes derived from human plasma as well as the investigation of their immune modulatory potential and the diagnostic and prognostic value of exosomes in HIV-1 pathogenesis.
Protocol
A general diagram of the exosome isolation and purification procedure is provided in Figure 1 . Whole blood was obtained from healthy volunteer donors and from HIV-positive individuals not receiving antiretroviral theraoy attending the Hope Clinic of Emory University and the Infectious Disease Program of Grady Health System in Atlanta, Georgia. This study was approved by the institutional review boards of Emory University and Morehouse School of Medicine. All persons participating in the study gave written and informed consent. 
Preparation of Exosomes from Blood Plasma

Preparation of Exosome Fraction from Plasma
1. Centrifuge plasma at 10,000 x g for 30 min at 4 °C to remove cellular debris. Use a sterile serological pipette to transfer the cleared plasma supernatant to a clean 25 ml ultracentrifuge tube. Discard the pellet in the biohazard container. 2. Centrifuge the cleared plasma at 100,000 x g for 2 hr at 4 °C to remove large vesicles. Remove the 100,000 x g supernatant carefully by pipetting, and discard in biohazard waste. Resuspend the 100,000 x g pellet in 1 ml of 1X PBS in a clean tube and incubate at RT for 30 min, swirling gently to dislodge and separate particles. 3. Wash the suspended 100,000 x g exosome/virus pellet by adding 25 ml of PBS. Gently invert the tube five times to mix, then centrifuge again at 100,000 x g for 2 hr at 4 °C. Discard the PBS wash solution in the biohazard waste container. 4. Resuspend the 100,000 x g pellet in 1 ml of 1 X PBS and incubate at RT for 30 min swirling gently to dislodge and dissolve the pellet.
NOTE: If it is not possible to proceed directly to the iodixanol gradient step, store the pellet, containing exosomes and virus particles, at 4 °C for 1-2 days until the iodixanol gradient step.
Purification of Exosomes
1. Generate 6%-18% velocity gradients of iodixanol using a dual-chamber gradient former apparatus. 1. Prepare 6% and 18% solutions of the iodixanol reagent, supplied as a 60% solution in water, by dilution in PBS. Pipet 5.5 ml of the 18% solution into the stirred chamber, and pipet 5.5 ml of the 6% solution into the reservoir chamber. Turn on the stirrer, open the stopcock, and allow each gradient to flow into a 14 ml ultracentrifuge tube. NOTE: Either use immediately or store prepared gradients O/N at 4 °C prior to use. 2. Carefully layer 1 ml of the exosome/virus solution onto the top of each 11 ml gradient. Centrifuge gradients at 250,000 x g for 2 hr at 4°C
, using a SW40Ti swinging bucket rotor. 3. Label twelve (12) 1.5 ml microcentrifuge tubes. Remove 1.0 ml from the top of the gradient and transfer to tube #1. Transfer the remaining 1ml fractions to tubes 2-12 in sequential order. NOTE: The topmost fraction will thus be #1, the bottom fraction, #12. Store the gradient fractions at 4 °C. The purified exosomes, which should be in the fractions 1-3 at the top of the gradient, are stable for 3-4 weeks when stored at 4 °C.
Exosome Characterization
1. Acetylcholinesterase (AChE) Activity Assay 1. Prepare 100 mM substrate stock by mixing acetylthiocholine iodide 28.9 mg in 1 ml of 1X PBS. Store substrate stock at -20 °C up to 1 month.
2. Prepare 10 mM color indicator stock by mixing benzoic acid 39.6mg and sodium bicarbonate 15 mg in 10 ml of 1X PBS. Store color indicator stock at 4 °C up to two weeks. 3. Prepare assay reagent by mixing 1X PBS, substrate, and color indicator in a ratio of 100:2:5 (for example, 10 ml 1X PBS + 200 μl substrate + 500 μl color indicator). 4. Transfer 50 μl from each 1.5 ml gradient fraction tube (labeled 1-12, from procedure III.3) to the wells of a 96-well microtiter plate.
Prepare duplicate wells for each gradient sample. 5. Prepare a set of standards by first making a 2000 μU/ml AChE stock in PBS. Make eleven (11) 2-fold serial dilutions of this stock and add 50 μl of each dilution to a single well of a microtiter plate, so that standard #1 = 2,000 μU/ml, #2 = 1,000 μU/ml, #3 = 500 μU/ml, etc. until #12 = 0.98 μU/ml. The twelve AchE standards will thus occupy a single row of a 96-well assay plate. 6. Add 200 μl of assay reagent mixture to each well and incubate 20 min (in the dark) at RT to allow development of the colored reaction product. Measure AChE activity at a wavelength of 450 nm using a fluorescent microplate reader. NOTE: The percentage of starting material remaining after exosome purification is assessed by AchE assay of the unfractionated plasma.
2. Immunoblot Analysis 1. Separate proteins in gradient fractions 1-12 (from procedure 2. the HRP-labeled proteins Detect the chemiluminescent signal using an electronic imaging system with CCD camera. 6. Save the images as TIFF files which can be viewed in Adobe Photoshop. Perform densitometry analysis of bands using ImageJ software (National Institutes of Health, Bethesda, MD).
3. Cytokine Assay 1. Prior to the cytokine assay, disrupt immune complexes that are usually present in human plasma by acid dissociation and lyse the exosomes by detergent treatment. Assay both starting plasma samples and purified exosome preparations. 1. To 100 μl of human plasma add 100 μl 0.33 N HCL and incubate at 37 °C for 1 hr. Add 100 μl 0.33 N NaOH to neutralize acidtreated plasma. Add Triton X-100 to both the neutralized plasma and purified exosome samples, to a final concentration of 1%, to cause lysis of exosomes.
2. For this assay (a fluorescent bead-based procedure), use magnetic beads pre-coated with antibodies by the manufacturer. Use a custom-designed panel of anti-human cytokine antibody-coated beads; listed in Table 1 . Vortex the antibody-coated magnetic beads from the cytokine assay kit for 30 sec and add 50 μl beads to each well of a 96-well plate to be used in the assay. 3. Prepare a dilution series of standards in plasma standard buffer (both contained in the cytokine assay kit) as described in the instruction manual for the cytokine assay kit, to generate an 8-point standard curve. 4. Add 150 μl of 1X wash buffer (from kit) to each well and wash the beads using a magnetic bead washer, as described in the manual.
Add 25 μl plasma assay buffer (from kit) to each well. Add 25 μl of standards and samples to all wells used in the assay. Add 25 μl of plasma sample buffer to negative control wells. Seal and shake the plate at 700 rpm for 60 min at RT and incubate O/N at 4 °C. 5. Add 150 μl of 1X wash buffer to each well and wash the plate (as in step 3.3.4, above). Add 25 μl of detection antibodies into each well, seal and shake plate at 700 rpm for 30 min at RT. Repeat the washing step. 6. Add 50 µl of streptavidin solution (SAPE, from kit) into each well, seal and shake plate at 700 rpm for 30 min at RT. Repeat plate washes as in 3.3.4. 7. Add 120 µl of reading buffer (from kit) into each well and shake on a laboratory tabletop shaker at 700 rpm for 5 min at RT to allow the fluorescent signal to develop. Read plate on the plate reader as per the manufacturer's instructions. 8. In order to account for the amount of exosomes lost during the isolation procedure, use the following equation: [(original reading / plasma volume) x 66.6= adjusted cytokine reading].
Assay for Immunomodulatory Potential
1. Preparation of Culture Medium with Exosome-depleted Fetal Bovine Serum 1. Centrifuge 500 ml of fetal bovine serum (FBS) at 100,000 x g for 20 hr at 4 °C to pellet contaminating exosomes and microvesicles. Carefully remove and save the exosome-depleted FBS supernatant. Discard the pellet in the biohazard waste. 2. Combine 20% of the exosome-depleted FBS supernatant with 500 ml of Roswell Park Memorial Institute 1640 (RPMI 1640) medium.
Filter the medium through a 0.45 µm membrane filter. 3. Add streptomycin (100 U/ml), penicillin (100 U/ml), L-glutamine (2 mM), HEPES-buffered saline solution (10 µM), and IL-2 (20 U/ml) to the filtered medium. 
Discussion
Chronic immune activation (CIA) and CD4+ T cell depletion are two important hallmarks of HIV-1 infection. They have been established as predictors for pathogenesis, with CIA being the best predictor. However, the underlying mechanisms driving chronic systemic immune activation and CD4+ T cell decline still have not been fully elucidated. We and other labs have developed firm evidence that exosomes secreted from HIV-1 infected cells play a role in both hallmarks.
The continuing interest in both composition and function of extracellular vesicles has led to the publication of various methods for exosome isolation from both cell culture media and biological fluids [24] [25] [26] . However, a barrier to investigating the role of exosomes in HIV-1 pathogenesis has been the efficient separation of exosomes from HIV-1 particles while maintaining the ability to investigate both exosome content and functional activity. We have developed a protocol for purification of exosomes from HIV-1 particles in human plasma , utilizing iodixanol velocity gradients. The HIV-positive donors used in this study had not received antiretroviral treatment and the plasma samples used for these experiments contained from 1500 to 400,000 virus particles/mL with an average of 206,000 virus particles/ml 21 . Thus, we demonstrate that exosomes in the plasma of HIV-1 infected individuals can be efficiently separated from HIV-1 virus particles, even when the virus loads are high. Though similar in size and density, exosomes segregated in the low-density/upper fractions of the iodixanol gradients as compared to viral particles, which segregated in the high-density/lower fractions. The exosomes prepared by the iodixanol gradient method are highly purified and free of contaminating extracellular proteins. The purity of the isolated exosomes population was confirmed using p24 ELISA and Western blot analysis for HIV-1 p24 capsid protein as well as Western analysis for exosomal markers, AChE, CD9, CD45, and CD63. Use of these markers is consistent with recently published guidelines for exosome identification 27 .
More physiologically relevant to immune activation, the purified exosomes from HIV-1 infected individuals were found to contain cytokines/ chemokines at significantly higher concentrations than exosomes from HIV-1 seronegative controls. Moreover, exosomes from HIV-1 infected individuals were biologically active, exhibiting the ability to induce increased levels of the activation marker, CD38, on the surface of naïve and central memory CD4+ and CD8 + T cells. Collectively, these data suggest a mechanism that could drive persistent immune activation during HIV infection.
The results we were able to obtain using our exosome purification process, which combines differential centrifugation and iodixanol velocity gradient separation show the value of using highly purified exosomes for physiological and functional bioassays. The procedure does have certain pitfalls and limitations. A considerable amount of the exosomes, often a majority of the starting material as calculated by measurements of AChE activity, are lost during the process. In addition, the procedure is also time consuming and requires access to expensive equipment. Finally, the generation of the iodixanol gradients using the gradient fromer apparatus requires considerable practice to ensure reproducibility. An
